Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 26, 2015 7:31 AM ET

Pharmaceuticals

Company Overview of Bayer Pharma AG

Company Overview

Bayer Pharma AG develops drugs and therapeutics for cardiovascular and blood diseases, oncological diseases, ophthalmology, and women's health. It offers prescription medicines for cardiovascular and blood diseases that include heart attack, high blood pressure, peripheral arterial occlusive disease, pulmonary hypertension, stroke, and thrombosis; oncological diseases, such as breast cancer, liver cancer, non-Hodgkin lymphoma, prostate cancer, and renal cell cancer; and ophthalmology diseases, including age-related macular degeneration. The company also offers prescription medicines for hormonal contraception, endometriosis, gynecological diseases, menopausal complaints, and premenstrual dys...

Müllerstrasse 178

Berlin,  13353

Germany

Founded in 1851

10,273 Employees

Phone:

49 30 468 11 11

Fax:

49 30 468 15305

Key Executives for Bayer Pharma AG

Chief Executive Officer and Chairman of Management Board
Age: 52
Chief Financial Officer and Member of Management Board
Age: 57
Senior Vice President
Head of Specialized Therapeutics Business Area
Head of Latin American Canada Region Operations
Compensation as of Fiscal Year 2014.

Bayer Pharma AG Key Developments

OncoMed Pharmaceuticals, Inc. Announces Selection of First Small Molecule Product Under Collaboration With Bayer Pharma AG

OncoMed Pharmaceuticals, Inc. announced selection of first small molecule product candidate targeting the Wnt pathway under collaboration with Bayer Pharma AG. The small molecule product candidate is advancing to preclinical development triggering a $2 million milestone payment to OncoMed. OncoMed and Bayer initiated joint discovery efforts to identify small molecule inhibitors of the Wnt pathway, a key cancer stem cell pathway, as part of the companies' collaboration initiated in 2010. This is the first small molecule inhibitor of a cancer stem cell pathway from the collaboration to enter preclinical development. Bayer will lead development and commercialization of Wnt small molecule product candidates.

Statute of Limitations Bars Claims Alleging Bayer Healthcare Pharmaceuticals Inc., Bayer Pharma AG and Bayer Healthcare Pharmaceuticals's IUD Perforated Patient's Uterus

Dismissing as time-barred claims arising from injuries a claimant suffered when an intrauterine device (IUD) migrated into her abdomen, the U.S. District Court for the Southern District of New York concluded that the statute of limitations began to run when the claimant should have been on notice of a possible connection between her injuries and the device. Bayer Healthcare Pharmaceuticals Inc., Bayer Pharma AG and Bayer Healthcare Pharmaceuticals (Bayer) manufactures Mirena, an IUD designed to prevent pregnancy for up to five years. On April 30, 2009, Dr. Cathy Carr inserted Mirena into a patient. In early July 2011, the patient began to experience nausea and vomiting. On July 7, 2011, Carr examined the patient and informed her the IUD may have moved. The patient went to the emergency room on July 8 and July 9, 2011. An examination revealed the IUD perforated the patient's uterus and migrated to her lower abdomen. The patient underwent emergency surgery to remove the IUD. She sued Bayer on Sept. 26, 2013. Bayer moved to dismiss on statute of limitations grounds. The district court observed that a two-year statute of limitations applied to the patient's defective design and manufacture, failure to warn and strict liability claims. The patient contended the statute of limitations did not begin to run until May 2013 when she saw a commercial that linked the injuries she suffered to Mirena. The district court disagreed. The statute of limitations for product liability claims accrues when a plaintiff knows or should know through the exercise of ordinary diligence that a product harmed her and she should inquire into her legal rights. By July 8 or 9, 2011, the patient knew she was injured and that the injury was in some way caused by Bayer's device. The patient, however, did not file suit until more than two years later so her products liability claims were untimely. The patient argued her suspicion that she was injured as a result of her doctor's negligence, as opposed to any negligence by Bayer, tolled the statute of limitations. The district court determined the existence of an alternative explanation for the patient's injuries did not mean the information the patient possessed on July 8 or 9, 2011, was insufficient to prompt her to investigate the device's role in causing her injuries.

arGEN-X Announces Collaboration with Bayer Pharma AG to Discover and Develop Therapeutic Antibody Candidates

arGEN-X announced the initiation of a collaboration with Bayer Pharma AG, leveraging arGEN-X's SIMPLE Antibody(TM) technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms. With this collaboration, arGEN-X will apply its SIMPLE Antibody(TM) technology to multiple targets submitted by Bayer. The parties will work together to validate human antibody leads in disease-relevant models, with Bayer being responsible for further preclinical and clinical development and commercialization of therapeutic antibody products. Under the terms of the Agreement, Bayer will pay arGEN-X an upfront technology access fee, research support and technical success-based milestones. Bayer will also pay clinical, regulatory and product sales-based milestones as antibody programs progress through clinical development and registration.

Similar Private Companies By Industry

Company Name Region
Merckle GmbH Europe
Warburg Glycomed GmbH Europe
Excella GmbH Europe
Curadis GmbH Europe
Migragen AG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bayer Pharma AG, please visit www.bayerpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.